

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## Continuous Glucose Monitoring Metrics for Earlier Identification of Prediabetes: Protocol for a Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061756
Article Type:	Protocol
Date Submitted by the Author:	07-Feb-2022
Complete List of Authors:	Gottfried, Sara; Thomas Jefferson University Hospitals, Department of Integrative Medicine and Nutritional Sciences Pontiggia, Laura; Thomas Jefferson University Hospitals, Institute of Emerging Health Professions (IEHP), College of Health Professions Newberg, Andrew; Thomas Jefferson University Hospitals, Department of Integrative Medicine and Nutritional Sciences Laynor, Gregory; Thomas Jefferson University, Information Services, Scott Memorial Library Monti, Daniel; Thomas Jefferson University Hospitals, Department of Integrative Medicine and Nutritional Sciences
Keywords:	PREVENTIVE MEDICINE, PRIMARY CARE, Physiology < NATURAL SCIENCE DISCIPLINES

SCHOLARONE™  
Manuscripts

1  
2  
3 **TITLE** Continuous Glucose Monitoring Metrics for Earlier Identification of Prediabetes:  
4 Protocol for a Systematic Review and Meta-Analysis  
5

6 *Sara Gottfried<sup>1</sup>, Laura Pontiggia<sup>2</sup>, Andrew Newberg<sup>1,3</sup>, Gregory Laynor<sup>4</sup>, Daniel Monti<sup>1</sup>*  
7  
8

9  
10 <sup>1</sup> Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University,  
11 Philadelphia, PA, 19107  
12

13 <sup>2</sup> Institute of Emerging Health Professions (IEHP), College of Health Professions, Thomas  
14 Jefferson University, Philadelphia, PA, 19107  
15

16 <sup>3</sup> Department of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107  
17

18 <sup>4</sup> Information Services, Scott Memorial Library, Thomas Jefferson University, Philadelphia, PA  
19 19107  
20  
21

22  
23 **Please address all correspondence to:**  
24

25 Sara Gottfried, MD  
26 Department of Integrative Medicine and Nutritional Sciences  
27 Thomas Jefferson University  
28 925 Chestnut Street, Suite 120, Philadelphia, PA 19107  
29 E-mail: [sara.gottfried@jefferson.edu](mailto:sara.gottfried@jefferson.edu)  
30 Phone: 510-207-0361  
31 Fax: 215-955-2509  
32  
33

34 Key words:  
35 Continuous glucose monitoring  
36 Glucose variability  
37 Prediabetes  
38  
39

40 Word Count: 3666  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## ABSTRACT

**Introduction:** Glycaemic variability is not well characterized in nondiabetic subjects. More comprehensive sampling as obtained with continuous glucose monitoring (CGM) may improve diagnostic accuracy of the transition from health to prediabetes. Our goal is to investigate the glycaemic system as it shifts from health to predisease in nondiabetic patients utilizing CGM metrics. New insights may offer therapeutic promise for reversing dysglycaemia more successfully with dietary, nutritional, and lifestyle change before progression occurs to prediabetes and diabetes.

**Methods and analysis:** This systematic review will include comprehensive searches of the PubMed, Scopus, Cochrane Library, and ClinicalTrials.gov databases, with restrictions set to studies published in the last 10 years in English. Reference lists of studies that meet eligibility criteria in the screening process will subsequently be screened for the potential inclusion of additional studies. We will include studies that examine CGM use and report diagnostic criteria such as fasting glucose and/or haemoglobin A1C (HbA1c) such that we can assess correlation between CGM metrics and established diagnostic criteria and describe how CGM metrics are altered in the transition from health to prediabetes. The screening and data extraction will be conducted by two independent reviewers using Covidence. All included papers will also be evaluated for quality and publication bias using Cochrane Collaboration risk of bias tools. If there are two or more studies with quantitative estimates that can be combined, we will conduct a meta-analysis after assessing heterogeneity.

**Ethics and dissemination:** The systematic review methodology does not require formal ethical review due to the nature of the study design. Study findings will be publicly available and published in a peer-reviewed journal.

*Prospero registration number:* submitted on 2/1/22, CRD pending

## STRENGTHS AND LIMITATIONS OF THIS STUDY

- To our knowledge, this will be the first systematic review and meta-analysis to compare continuous glucose monitoring metrics with the gold standard for diagnosis of health or prediabetes in a nondiabetic population.
- The evidence is determined through a systematic search in four biomedical databases and targeted searching of the grey literature in relevant conference proceedings.
- The Covidence systematic review software will be used for blinded screening, conflict resolving, data extraction, and quality assessment by three independent reviewers.
- The Cochrane Collaboration risk of bias tools will be used for evaluating quality and risk of bias.
- Limitations include a bias for studies published in English in the past 10 years.

## INTRODUCTION

Rates of prediabetes and diabetes continue to increase in prevalence. Prediabetes affects 88 million adults, more than 1 in 3 US adults.[1] However, most people with prediabetes are undiagnosed or unaware. Prediabetes is thought to be an intermediate state of hyperglycaemia with glycemic parameters above normal but below the diabetes threshold. Further, the gold standard of blood sugar measurement from the American Diabetes Association—fasting glucose,

glycosylated haemoglobin (Haemoglobin A1C or HbA1c), and oral glucose tolerance testing in response to a 75-gram glucose load[2]—are limited because they diagnose dysglycaemia late in the pathophysiological process when it may be more difficult to reverse. Prediabetes represents worsening fasting glucose and/or impaired glucose tolerance, but definitions vary, leading to significant practice disparity and low guideline adherence.[3] Additionally, there are racial and gender disparities in prediabetes screening.[4]

Glycaemic variability is not well characterized in nondiabetic subjects. Normal glucose (euglycaemia) variability on a moment-to-moment basis has yet to be elucidated. Most standards of euglycaemia rely on targets from epidemiologic studies of episodic measurement, which document clinical labs measured annually rather than a more comprehensive characterization of the individual's glycaemic status. People with similar HbA1C and mean glucose show extremely different daily glucose excursions and variability, leading to debate and lack of consensus about pathophysiological pathways in the gradient from health to disease.[5] Indeed, standard measurements like HbA1C are limited because several conditions affect reliability, including patient ethnicity; conditions that impair erythrocyte production or alter the normal process of glycation; and even normal aging.[6, 7] Moreover, fasting glucose of 100 mg/dL may not be sufficient to separate normoglycemic from prediabetic individuals. Subjects with fasting glucose less than 100 mg/dL show impaired glucose tolerance when monitored continuously for at least 24 hours.[8] Subjects who are morbidly obese who are euglycaemic have higher glycemic variability compared with normal weight, nondiabetic subjects.[9] Some investigators use a fasting plasma glucose level  $\leq 5.4$  mmol/l (97 mg/dl) after an overnight fast because it has greater sensitivity to exclude diabetes in the absences of an Oral Glucose Tolerance Test (OGTT).[10] Evidence supports increased insulin resistance and up to a three-fold greater risk of diabetes when fasting glucose exceeds 90 mg/dl.[11]

Excess glycaemic variability, especially postprandial, triggers increased oxidative stress that can damage tissues, such as blood vessels.[12, 13, 14] Glycaemic variability within the gold standard of “normal” may raise cardiovascular risk and precede an increase in HbA1c.[15] Glycaemic variability may modulate cardiovascular risk even when fasting glucose and A1C are normal.[16] While most of the data on downstream damage from excess glucose excursions are derived from diabetic patients, the scientific literature increasingly indicates that micro- and macro-vascular complications may occur in nondiabetic subjects.[17, 18, 19] Risk may be higher in women at lower glucose levels compared to men.[20, 21] Evidence shows that characterizing dysglycaemia with greater precision uncovers higher cardiometabolic risk associated with specific glucose derangements such as postprandial hyperglycaemia,[22, 23] acute glucose spikes,[24, 25] and perhaps nocturnal hypoglycaemia.[26, 27, 28, 29] From a systems biology perspective, the convention of single or limited series measurement of glucose testing may be inadequate to detect downstream dysfunction, setting the stage for more dense sampling and real-world evidence as obtained with continuous glucose monitoring (CGM) and potentially better diagnostic accuracy.[30]

Our goal is to interrogate the glycemic system as it shifts from health to predisease in nondiabetic patients utilizing CGM metrics. New insights may offer therapeutic promise for reversing dysglycaemia more successfully with dietary, nutritional, and lifestyle change before progression occurs to prediabetes and diabetes.

## Objectives

This systematic review aims to answer the questions:

1. How do continuous glucose monitoring metrics differ between euglycaemia and prediabetes?
2. What is the relation (correlation) between CGM dynamic metrics and established diagnostic criteria?
3. What is the diagnostic power of CGM dynamic metrics?

## METHODS AND ANALYSIS

The protocol for the present systematic review and meta-analysis follows the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines,[31] and the Cochrane Handbook of Systematic Reviews of Interventions.[32]

The protocol has been submitted for registration with the National Institute for Health Research (NIHR) International Prospective Register of Systematic Reviews (CRD pending).

### Eligibility criteria

A summary of the participants, interventions, comparators and outcomes considered, as well as the type of studies included according to PICOS strategy,<sup>33</sup> is provided below.

#### Population

The target population is adults (> 18 years old) who are diagnosed with prediabetes (fasting glucose 100-125 mg/dL after a minimum 8-hour fast, and/or hemoglobin A1C 5.7-6.4%, and/or 2-hour oral glucose tolerance test with glucose 140-199 mg/dL) as defined by the American Diabetes Association (ADA), <https://www.diabetes.org/a1c/diagnosis>, accessed January 24, 2022. We will use the criteria of fasting glucose 100-125 mg/dL or hemoglobin A1C of 5.7-6.4% since the 2-hour oral glucose tolerance test is less commonly used in clinical practice, but we will extract the data if available. Studies that include only participants above the age of 65 or diagnosed with Type 1 and/or Type 2 diabetes will be excluded. Studies will also be excluded if focused on subjects with acute illness or systemic chronic disease (e.g., liver, kidney, stroke, coronary artery disease).

#### Intervention

We will evaluate primary studies that report outcomes of the use of CGM in patients with prediabetes and/or healthy subjects.

#### Comparison

Potentially relevant CGM biomarkers are identified by comparing prediabetes values to values for healthy controls (fasting glucose < 100 mg/dL, and/or hemoglobin A1C < 5.7%, and/or 2-hour oral glucose tolerance test with glucose <140 mg/dL). CGM biomarkers are then compared to standard diagnostics for prediabetes.

#### Outcomes

In order to explore and define novel CGM biomarkers to predict transition from normal to prediabetic phenotype, the following outcomes are considered:

- CGM metrics (e.g., SD, CV, CONGA, MAGE, MAG, M-value, HBGI, LBGI, J-index, L-index, GRADE, % Time in range, % Time below range, % Time above range)
- Pearson correlation coefficient and results of error grid analysis between the CGM system metrics and established glucose monitoring methods (fasting glucose, hemoglobin A1C, 2-hour oral glucose tolerance test).
- CGM metrics diagnostic power (e.g., sensitivity, specificity, area under the curve, diagnostic odds ratio).

### Study design

This review includes observational (e.g., case report, case series, cross-sectional, case-control, cohort) and interventional (e.g., quasi-experimental studies, randomized controlled trials, community trials, field trials) primary, peer-review studies in which CGM is the only intervention under investigation. We will exclude reviews, editorials, commentaries, letters, opinions, meta-analysis, case reports, conference abstracts, comments, preclinical (in-vitro; animal model) studies, and clinical trials involving additional interventions. Studies will be restricted to the English language and published in the last 10 years.

### **Search methods for identifying studies**

#### Sources of studies

We will conduct systematic searches of the PubMed, Scopus, Cochrane Library, and ClinicalTrials.gov databases. Searches will be limited to studies published in English within 10 years of the time of conducting the search. We will additionally search for unpublished studies in grey literature, by reviewing abstracts from a targeted group of conference proceedings for potential inclusion of additional studies. When available, the proceedings of these conferences from 2012 to 2022 will be searched: Precision Nutrition and Metabolism Conference; Harvard Precision Medicine Annual Conference; International Precision Medicine Conference; and Precision Medicine World Conference.

#### Search strategy

A medical librarian on the review team developed a comprehensive search strategy encompassing the aims of the systematic review. The strategy combines four sets of terms with Boolean operators: 1) terms related to prediabetes; 2) terms related to continuous glucose monitoring; 3) terms related to diagnostic criteria for prediabetes; and 4) terms related to diagnostic accuracy and the prediction of transition. Each set of terms includes both keywords searched in the title/abstract field and database-specific subject headings. Terms within each set are combined with the operator OR. The four sets of terms are then combined with the operator AND, yielding studies that include at least one term from each set. The initial search strategy was developed in PubMed (see online supplementary file 1). The strategy will be translated into the other included databases, using appropriate subject headings for each database.

#### Study selection

All records identified in the database search will be uploaded to Covidence systematic review software (<https://www.covidence.org>) for automatic deduplication and blinded screening, conflict resolving, study selection and data extraction. Two authors will independently perform the initial primary article screening based on the information contained in their titles and abstracts, and categorize them into three groups: relevant, irrelevant and unsure. In case of disagreement, the article will be re-evaluated and, if the disagreement persists, a third reviewer will make a final decision. Full-paper screening will then be conducted by the same independent investigators and a list of articles to be included in the review is compiled. Reference lists of articles that meet eligibility criteria in the screening process will subsequently be screened for potential inclusion of additional studies.

### Data extraction

Two independent authors will extract data from the final studies identified as eligible to be included in the review using a predesigned pilot-tested data collection form using the Covidence extraction module. Eventual discrepancies will be addressed with a third reviewer and discussed until consensus is reached.

The data to be extracted will include:

1. Publication details: authors, title, journal, year of publication, country in which the study was conducted and funding source(s).
2. Study design: type of study, inclusion and exclusion criteria, method of recruitment of participants, limitations and mitigation strategies.
3. Participant details: sample size, demographic information (e.g. age, gender, comorbidities).
4. Intervention characteristics: CGM device, aim of intervention.
5. Study outcomes: CGM metrics, correlation between CGM metrics and established diagnostic criteria.

In cases of missing, incomplete, or unclear data in the included studies, we will attempt to contact study authors for further information.

### Risk of Bias

The Cochrane Collaboration risk of bias tools will be used to assess the risk of bias in the studies that meet inclusion criteria.<sup>[34, 35, 36]</sup> This will be assessed independently by two reviewers, with conflicts resolved by a third reviewer.

### Data synthesis and analysis

Data will be entered into a custom database and a narrative synthesis will summarize the findings of the review by organizing data into a systematic narrative review, tables, and figures of data extraction. For continuous outcomes analysis will be performed using standardized mean differences (SMD) or mean differences (MD) with its respective 95% CIs. Binary outcomes will be analyzed and reported using risk ratio (RR) or odds ratio (OR) with its respective 95% CIs. Studies with similar characteristics and outcomes will be grouped and, where suitable data and homogeneity exist, a meta-analysis will be performed using random effects models. A combined Pearson correlation coefficient between CGM metrics and established diagnostic criteria (i.e., fasting plasma glucose, hemoglobin A1C, 2-hour oral glucose tolerance test) and according 95% CI will also be calculated. If sufficient data are available, subgroup analysis will be carried out to



1  
2  
3 explore CGM metrics estimates for prediabetes stratified by age, sex, race and ethnicity, and  
4 body mass index.  
5

### 6 **Patient and Public Involvement**

7 As this research will be based on previously published data, there will be no patient and  
8 members of the public involvement in the design, interpretation or dissemination of the findings.  
9

## 10 **DISCUSSION**

11  
12  
13 This systematic review will provide important information about the benefits of adding CGM to  
14 standard diagnostic measures in the diagnosis of euglycaemia versus prediabetes. Currently,  
15 there are many challenges that exist with the diagnosis of prediabetes.[37] The technology,  
16 emerging algorithms, and more comprehensive data set have shown promise distinguishing  
17 euglycemic from prediabetic subjects at an earlier stage, and likely before standard measures  
18 such as HbA1C show abnormalities. Previously, Hall et al. discovered that in individuals  
19 considered to be euglycemic by single or episodic measurement, CGM identifies an additional  
20 15% of patients with prediabetes and 2% with diabetes, suggesting that dysglycaemia is more  
21 prevalent than previously understood and that CGM metrics may be a more sensitive indicator of  
22 dysglycaemia.[38] The findings will inform further work that will aim to more fully characterize  
23 the stages in the transition from health to prediabetes, potentially providing a mechanism for  
24 patients to be more involved and empowered to reverse dysglycaemia in response to food and  
25 lifestyle factors. There are two clear limitations to the current review protocol. The review will  
26 be restricted to published studies in the last 10 years, which introduces publication bias.  
27 Secondly, only studies written in English language will be included, introducing language bias.  
28  
29  
30

### 31 **Ethics and dissemination**

32 Owing to the study design of systematic reviews and meta-analyses, ethics approval is not  
33 necessary. The systematic review will be published in a peer-reviewed journal and presented at  
34 appropriate conferences. This protocol will be adapted for the analysis of other classes of  
35 biomarkers for prediabetes.  
36  
37  
38

### 39 **Authors' contributions**

40 SG was involved with conceptualization, methodology, preliminary systematic review, formal  
41 analysis, writing the protocol manuscript, study supervision, and project administration; LP was  
42 involved in project conception and development, methodology, preliminary systematic review,  
43 formal analysis, study supervision, acquisition of data, data analysis and writing the protocol;  
44 AN was involved in conceptualization, study supervision and writing the manuscript; GL was  
45 involved in systematic review search strategy development, registration of the protocol in  
46 Prospero, and writing of the protocol manuscript; DM was involved in project conception and  
47 development, and writing the protocol manuscript. All authors read and approved the final  
48 manuscript.  
49  
50

### 51 **Funding statement**

52 This work is supported by a restricted gift from Levels Health.  
53

### 54 **Competing interests**

None

## REFERENCES

- <sup>1</sup> Centers for Disease Control and Prevention. What is diabetes? <https://www.cdc.gov/diabetes/basics/diabetes.html>, accessed 3/19/21
- <sup>2</sup> American Diabetes Association: Standards of medical care in diabetes—2007. *Diabetes Care* 2007;30(Suppl1):S4–S41.
- <sup>3</sup> Tseng E, Greer RC, O'Rourke P, *et al.* National Survey of Primary Care Physicians' Knowledge, Practices, and Perceptions of Prediabetes. *J Gen Intern Med.* 2019;34(11):2475-2481. doi:10.1007/s11606-019-05245-7
- <sup>4</sup> Thomas TW, Golin C, Samuel-Hodge CD, *et al.* Race and gender differences in abnormal blood glucose screening and clinician response to prediabetes: A mixed-methods assessment. *Prev Med.* 2021;148:106587.
- <sup>5</sup> Siegelaar SE, Holleman F, Hoekstra JB, *et al.* Glucose variability: does it matter? *Endocr Rev* 2010;31:171–182.
- <sup>6</sup> Weykamp, C. HbA1c: a review of analytical and clinical aspects. *Annals of laboratory medicine* vol 2013;33(6): 393-400.
- <sup>7</sup> Shepard JG, Airee A, Dake AW, *et al.* Limitations of A1c Interpretation. *Southern medical journal* vol. 108,12 (2015): 724-9.
- <sup>8</sup> Nomura K, Saitoh T, Kim GU, *et al.* Glycemic profiles of healthy individuals with low fasting plasma glucose and HbA1c. *ISRN Endocrinology.* 2011;2011(435047):6.
- <sup>9</sup> Salkind S, Huizenga R, Fonda S, *et al.* Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature. *J Diabet Sci Technol* 2014;8(5):1042–7.
- <sup>10</sup> Genuth S, Alberti KG, Bennett P, *et al.* Expert committee on the diagnosis and classification of diabetes mellitus. follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care.* 2003;26(11):3160-7.
- <sup>11</sup> Brambilla P, La Valle E, Falbo R, *et al.* “Normal fasting plasma glucose and risk of type 2 diabetes.” *Diabetes care* vol. 34,6 (2011): 1372-4.
- <sup>12</sup> Monnier L, Mas E, Ginet C, *et al.* Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA.* 2006;295(14):1681-7.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 
- 13 Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation*. 2002;106(16):2067-72.
- 14 Altıncık A, Tuğlu B, Demir K, et al. Relationship between oxidative stress and blood glucose fluctuations evaluated with daily glucose monitoring in children with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2016;29(4):435-9.
- 15 Hanefeld M, Sulk S, Helbig M, et al. Differences in glycaemic variability between normoglycemic and prediabetic subjects. *J Diabet Sci Technol*. 2014;8(2):286–90.
- 16 Buscemi S, Re A, Batsis JA, et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes. *Diabetes Med* 2010;27:872–8.
- 17 Buscemi S, Re A, Batsis JA, et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes. *Diabetes Med* 2010;27:872–8.
- 18 Luchsinger JA, Tang MX, Shea S, et al. “Hyperinsulinemia and risk of Alzheimer disease.” *Neurology* 2004;63(7): 1187-92.
- 19 Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. “Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.” *Lancet* 2010;375(9733):2215-22.
- 20 Lawlor DA, Fraser A, Ebrahim S, et al. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. *PLoS Med*. 2007 Aug;4(8):e263
- 21 Ahn SV, Kim HC, Nam CM, et al. Sex difference in the effect of the fasting serum glucose level on the risk of coronary heart disease. *J Cardiol*. 2018 Feb;71(2):149-154.
- 22 Ceriello A, Hanefeld M, Leiter L, et al. “Postprandial glucose regulation and diabetic complications.” *Archives of internal medicine* 2004;164(19):2090-5.
- 23 Shaw JE, Hodge AM, de Courten M, et al. “Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality.” *Diabetologia* 1999;42(9):1050-4.
- 24 Moore, KB. “Glucose fluctuations and oxidative stress.” *JAMA* 2006;296(14):1730.

- 1  
2  
3  
4 25 Sampson MJ, Gopaul N, Davies IR, et al. Plasma F2 isoprostanes: direct evidence of increased  
5 free radical damage during acute hyperglycemia in type 2 diabetes. *Diabetes Care*.  
6 2002;25(3):537-41.  
7  
8  
9 26 Zou CC, Liang L, Hong F, et al. "Glucose metabolism disorder in obese children assessed by  
10 continuous glucose monitoring system." *World journal of pediatrics: WJP* 2008;4(1): 26-30.  
11  
12 27 Lee D, Dreyfuss JM, Sheehan A, et al. Glycemic patterns are distinct in post-bariatric  
13 hypoglycemia after gastric bypass (PBH-RYGB). *J Clin Endocrinol Metab*. 2021;106(8):2291-  
14 2303.  
15  
16 28 Bialasiewicz P, Pawlowski M, Nowak D, et al. Decreasing concentration of interstitial glucose  
17 in REM sleep in subjects with normal glucose tolerance. *Diabet Med*. 2009;26(4):339-344.  
18  
19 29 Wang C, Lv L, Yang Y, et al. Glucose fluctuations in subjects with normal glucose tolerance,  
20 impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. *Clin Endocrinol*.  
21 2012;76:810-5.  
22  
23 30 Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose dysregulation.  
24 *PLoS Biology*. 2018;16(7):e2005143.  
25  
26 31 Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and  
27 meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1  
28  
29 32 Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version  
30 6.1). The Cochrane Collaboration; 2020. <http://www.handbook.cochrane.org>. Accessed January  
31 28, 2022.  
32  
33 33 The Cochrane Collaboration. Part 2 Chapter 3: Defining the criteria for including studies and  
34 how they will be grouped for the synthesis In: Higgins JPT, Green S. Cochrane handbook for  
35 systematic reviews of interventions (version 6.1). The Cochrane Collaboration; 2020.  
36 <http://www.handbook.cochrane.org>. Accessed January 28, 2022.  
37  
38 34 Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing  
39 risk of bias in randomised trials. *BMJ*. 2011;343:d5928. Published 2011 Oct 18.  
40 doi:10.1136/bmj.d5928  
41  
42 35 Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-  
43 randomised studies of interventions. *BMJ* 2016;355:i4919.  
44  
45 36 Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y,  
46 Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P,  
47 Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA,  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

1  
2  
3  
4 Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in  
5 randomised trials. *BMJ* 2019; **366**: 14898.  
6

7  
8 <sup>37</sup> Bansal N. Prediabetes diagnosis and treatment: A review. *World J Diabetes*. 2015;6(2):296-  
9 303. doi:10.4239/wjd.v6.i2.296.  
10

11 <sup>38</sup> Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose dysregulation.  
12 *PLoS Biology*. 2018;16(7):e2005143.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 (((("diabetes prevention" [title/abstract] OR "diabetes risk\*" [title/abstract] OR "diabetes susceptibility"  
4 [title/abstract] OR "prediabet\*" [title/abstract] OR "pre-diabet\*" [title/abstract] OR "prediabetic state"  
5 [mesh]) AND ("blood glucose self-monitoring" [mesh] OR "blood sugar self monitor\*" [title/abstract] OR  
6 "blood sugar self-monitor\*" [title/abstract] OR "CGM" [title/abstract] OR "CGMS" [title/abstract] OR  
7 "glucose monitor\*" [title/abstract] OR "glucose self monitor\*" [title/abstract] OR "glucose self-monitor\*" [title/abstract] OR "monitoring, ambulatory" [mesh] OR "monitoring, physiologic/instrumentation"  
8 [mesh] OR "monitoring, physiologic/methods" [mesh] OR "personalized medicine" [title/abstract] OR  
9 "precision medicine" [mesh] OR "precision medicine" [title/abstract] OR "RT-CGM" [title/abstract]))  
10 AND ("biomarker\*" [title/abstract] OR "biomarkers/analysis" [mesh] OR "biomarkers/blood" [mesh] OR  
11 "blood chemical analys\*" [title/abstract] OR "blood chemical analysis" [mesh] OR "blood glucose self-  
12 monitoring/statistics and numerical data" [mesh] OR "blood glucose/analysis" [mesh] OR "criteria"  
13 [title/abstract] OR "deviation\*" [title/abstract] OR "dysglycemia" [title/abstract] OR "euglycemi\*"  
14 [title/abstract] OR "euglycaemi\*"  
15 [title/abstract] OR "fluctuation\*" [title/abstract] OR "glucose tolerance  
16 test" [mesh] OR "glucose" [title/abstract] OR "glucotype\*" [title/abstract] OR "glycaemic" [title/abstract]  
17 OR "glycated hemoglobin A/analysis" [mesh] OR "glycated hemoglobin A/statistics and numerical data"  
18 [mesh] OR "glycemic" [title/abstract] OR "HbA1c" [title/abstract] OR "hemoglobin A1c" [title/abstract]  
19 OR "hyperglycemia" [mesh] OR "hyperglycemia" [title/abstract] OR "metric\*" [title/abstract] OR  
20 "normal\*" [title/abstract] OR "normoglycemic\*" [title/abstract] OR "phenotyp\*" [title/abstract] OR  
21 "prediabetic state/analysis" [mesh] OR "prediabetic state/blood" [mesh] OR "prediabetic state/blood"  
22 [mesh] OR "prediabetic state/statistics and numerical data" [mesh] OR "reference values" [mesh] OR  
23 "reference\*" [title/abstract] OR "screening\*" [title/abstract] OR "standard\*" [title/abstract] OR "test\*" [title/abstract] OR "variability" [title/abstract] OR "variation\*" [title/abstract])) AND ("detect\*" [title/abstract] OR "diagnos\*" [title/abstract] OR "disease progression" [mesh] OR "early diagnosis" [mesh] OR "early medical intervention" [mesh] OR "identif\*" [title/abstract] OR "prediabet\*" [title/abstract] OR "pre-diabet\*" [title/abstract] OR "prediabetic state/classification" [mesh] OR "prediabetic state/diagnosis" [mesh] OR "prediabetic state/prevention and control" [mesh] OR "prediabetic\*" [title/abstract] OR "pre-diabetic\*" [title/abstract] OR "predict\*" [title/abstract] OR "predictive value of tests" [mesh] OR "prevent\*" [title/abstract] OR "progression\*" [mesh] OR "risk assessment" [mesh] OR "risk factors" [mesh] OR "risk\*" [title/abstract] OR "transition\*" [title/abstract])) AND ((english[Filter])) AND ((y\_10[Filter]))  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



## PRISMA 2020 Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
<b>TITLE</b>			
Title	1	Identify the report as a systematic review.	Page 1
<b>ABSTRACT</b>			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	Page 1
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	Page 2
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	Page 3
<b>METHODS</b>			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Page 3, 4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	Pages 1, 4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Page 4, supplement
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	Page 4
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	Page 4, 5
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	Page 3, 4, 5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	Page 3, 4, 7
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	Page 1, 5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	Page 3, 4, 5
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	N/A
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	N/A
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	N/A
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	N/A
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	N/A

	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	N/A
1 2	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	N/A
3 4	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	Page 1



**PRISMA 2020 Checklist**

Section and Topic	Item #	Checklist item	Location where item is reported
<b>RESULTS</b>			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	N/A
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	N/A
Study characteristics	17	Cite each included study and present its characteristics.	N/A
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	N/A
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	N/A
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	N/A
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	N/A
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	N/A
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	N/A
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	N/A
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	N/A
<b>DISCUSSION</b>			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	Page 6
	23b	Discuss any limitations of the evidence included in the review.	Page 1, 6
	23c	Discuss any limitations of the review processes used.	
	23d	Discuss implications of the results for practice, policy, and future research.	
<b>OTHER INFORMATION</b>			
	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	Page 1



1	Registration and protocol	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	Page 1
2		24c	Describe and explain any amendments to information provided at registration or in the protocol.	N/A
3	Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	Page 7
4	Competing interests	26	Declare any competing interests of review authors.	Page 7
5	Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	N/A
6				
7				
8				
9				

10 From: Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. doi:  
 11 10.1136/bmj.n71

12 For more information, visit: <http://www.prisma-statement.org/>

For peer review only

136/bmjopen-2022-061756 on 25 August 2022. Downloaded from <http://bmjopen.bmj.com/> on April 23, 2024 by guest. Protected by copyright.

# BMJ Open

## Continuous Glucose Monitoring Metrics for Earlier Identification of Prediabetes: Protocol for a Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2022-061756.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Jul-2022
Complete List of Authors:	Gottfried, Sara; Thomas Jefferson University Hospitals, Department of Integrative Medicine and Nutritional Sciences Pontiggia, Laura; Thomas Jefferson University Hospitals, Institute of Emerging Health Professions (IEHP), College of Health Professions Newberg, Andrew; Thomas Jefferson University Hospitals, Department of Integrative Medicine and Nutritional Sciences Laynor, Gregory; Thomas Jefferson University, Information Services, Scott Memorial Library Monti, Daniel; Thomas Jefferson University Hospitals, Department of Integrative Medicine and Nutritional Sciences
<b>Primary Subject Heading</b>:	Nutrition and metabolism
Secondary Subject Heading:	Patient-centred medicine, Diabetes and endocrinology
Keywords:	PREVENTIVE MEDICINE, PRIMARY CARE, Physiology < NATURAL SCIENCE DISCIPLINES, GENERAL MEDICINE (see Internal Medicine), Health informatics < BIOTECHNOLOGY & BIOINFORMATICS

SCHOLARONE™  
Manuscripts

1 **TITLE** Continuous Glucose Monitoring Metrics for Earlier Identification of Prediabetes:  
2 Protocol for a Systematic Review and Meta-Analysis

3  
4  
5  
6  
7 *Sara Gottfried<sup>1</sup>, Laura Pontiggia<sup>2</sup>, Andrew Newberg<sup>1,3</sup>, Gregory Laynor<sup>4</sup>, Daniel Monti<sup>1</sup>*  
8

9  
10 <sup>1</sup> Department of Integrative Medicine and Nutritional Sciences, Thomas Jefferson University,  
11 Philadelphia, PA, 19107

12  
13 <sup>2</sup> Institute of Emerging Health Professions (IEHP), College of Health Professions, Thomas  
14 Jefferson University, Philadelphia, PA, 19107

15  
16 <sup>3</sup> Department of Radiology, Thomas Jefferson University, Philadelphia, PA, 19107

17  
18 <sup>4</sup> Information Services, Scott Memorial Library, Thomas Jefferson University, Philadelphia, PA  
19 19107  
20  
21

22  
23 **Please address all correspondence to:**

24  
25 Sara Gottfried, MD  
26 Department of Integrative Medicine and Nutritional Sciences  
27 Thomas Jefferson University  
28 925 Chestnut Street, Suite 120, Philadelphia, PA 19107  
29 E-mail: [sara.gottfried@jefferson.edu](mailto:sara.gottfried@jefferson.edu)  
30 Phone: 510-207-0361  
31 Fax: 215-955-2509  
32

33  
34 Key words:  
35 Continuous glucose monitoring  
36 Glucose variability  
37 Prediabetes  
38

39  
40 Word Count: 3877  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## 33 ABSTRACT

34  
35 **Introduction:** Glycaemic variability and other metrics are not well characterized in nondiabetic  
36 subjects. More comprehensive sampling as obtained with continuous glucose monitoring (CGM)  
37 may improve diagnostic accuracy of the transition from health to prediabetes. Our goal is to  
38 investigate the glycaemic system as it shifts from health to predisease in nondiabetic adult  
39 patients utilizing CGM metrics. New insights may offer therapeutic promise for reversing  
40 dysglycaemia more successfully with dietary, nutritional, and lifestyle change before progression  
41 occurs to prediabetes and diabetes.

42 **Methods and analysis:** This systematic review will include comprehensive searches of the  
43 PubMed, Scopus, Cochrane Library, and ClinicalTrials.gov databases, with restrictions set to  
44 studies published in the last 10 years in English and planned search date March 10, 2022.  
45 Reference lists of studies that meet eligibility criteria in the screening process will subsequently  
46 be screened for the potential inclusion of additional studies. We will include studies that examine  
47 CGM use and report diagnostic criteria such as fasting glucose and/or haemoglobin A1C  
48 (HbA1c) such that we can assess correlation between CGM metrics and established diagnostic  
49 criteria and describe how CGM metrics are altered in the transition from health to prediabetes.  
50 The screening and data extraction will be conducted by two independent reviewers using  
51 Covidence. All included papers will also be evaluated for quality and publication bias using  
52 Cochrane Collaboration risk of bias tools. If there are two or more studies with quantitative  
53 estimates that can be combined, we will conduct a meta-analysis after assessing heterogeneity.  
54 **Ethics and dissemination:** The systematic review methodology does not require formal ethical  
55 review due to the nature of the study design. Study findings will be publicly available and  
56 published in a peer-reviewed journal.

57 *Prospero registration number:* CRD42022308222

## 60 STRENGTHS AND LIMITATIONS OF THIS STUDY

- 62 • To our knowledge, this will be the first systematic review and meta-analysis to compare  
63 continuous glucose monitoring metrics with the gold standard for diagnosis of health or  
64 prediabetes in a nondiabetic population.
- 65 • The evidence is determined through a systematic search in four biomedical databases and  
66 targeted searching of the grey literature in relevant conference proceedings.
- 67 • The Covidence systematic review software will be used for blinded screening, conflict  
68 resolving, data extraction, and quality assessment by three independent reviewers.
- 69 • The Cochrane Collaboration risk of bias tools will be used for evaluating quality and risk  
70 of bias.
- 71 • Limitations include a bias for studies published in English in the past 10 years, with adult  
72 subjects in age range from 18 to 65 years.

## 74 INTRODUCTION

75  
76 Rates of prediabetes and diabetes continue to increase in prevalence. Prediabetes affects 88  
77 million adults, more than 1 in 3 US adults.[1] However, most people with prediabetes are  
78 undiagnosed or unaware. Prediabetes is thought to be an intermediate state of hyperglycaemia

79 with glycemic parameters above normal but below the diabetes threshold. Further, the gold  
80 standard of blood sugar measurement from the American Diabetes Association—fasting glucose,  
81 glycosylated haemoglobin (Haemoglobin A1C or HbA1c), and oral glucose tolerance testing in  
82 response to a 75-gram glucose load[2]—are limited because they diagnose dysglycaemia late in  
83 the pathophysiological process when it may be more difficult to reverse. Prediabetes represents  
84 worsening fasting glucose and/or impaired glucose tolerance, but definitions vary, leading to  
85 significant practice disparity and low guideline adherence.[3] Additionally, there are racial and  
86 gender disparities in prediabetes screening.[4]

87  
88 Glycaemic variability and other CGM metrics are not well characterized in nondiabetic subjects.  
89 Normal glucose (euglycaemia) variability on a moment-to-moment basis has yet to be  
90 elucidated. Most standards of euglycaemia rely on targets from epidemiologic studies of episodic  
91 measurement, which document clinical labs measured annually rather than a more  
92 comprehensive characterization of the individual's glycaemic status. People with similar HbA1C  
93 and mean glucose show extremely different daily glucose excursions and variability, leading to  
94 debate and lack of consensus about pathophysiological pathways in the gradient from health to  
95 disease.[5] Indeed, standard measurements like HbA1C are limited because several conditions  
96 affect reliability, including patient ethnicity; conditions that impair erythrocyte production or  
97 alter the normal process of glycation; and even normal aging.[6, 7] Moreover, fasting glucose of  
98 100 mg/dL may not be sufficient to separate normoglycemic from prediabetic individuals.  
99 Subjects with fasting glucose less than 100 mg/dL show impaired glucose tolerance when  
100 monitored continuously for at least 24 hours.[8] Subjects who are morbidly obese who are  
101 euglycaemic have higher glycemic variability compared with normal weight, nondiabetic  
102 subjects.[9] Some investigators use a fasting plasma glucose level  $\leq 5.4$  mmol/l (97 mg/dl) after  
103 an overnight fast because it has greater sensitivity to exclude diabetes in the absences of an Oral  
104 Glucose Tolerance Test (OGTT).[10] Evidence supports increased insulin resistance and up to a  
105 three-fold greater risk of diabetes when fasting glucose exceeds 90 mg/dl.[11]

106  
107 Excess glycaemic variability, especially postprandial, triggers increased oxidative stress that can  
108 damage tissues, such as blood vessels.[12, 13, 14] Glycaemic variability within the gold standard  
109 of “normal” may raise cardiovascular risk and precede an increase in HbA1c.[15] Glycaemic  
110 variability may modulate cardiovascular risk even when fasting glucose and A1C are  
111 normal.[16] While most of the data on downstream damage from excess glucose excursions are  
112 derived from diabetic patients, the scientific literature increasingly indicates that micro- and  
113 macro-vascular complications may occur in nondiabetic subjects.[17, 18, 19] Risk may be  
114 higher in women at lower glucose levels compared to men.[20, 21] Evidence shows that  
115 characterizing dysglycaemia with greater precision uncovers higher cardiometabolic risk  
116 associated with specific glucose derangements such as postprandial hyperglycaemia,[22, 23]  
117 acute glucose spikes,[24, 25] and perhaps nocturnal hypoglycaemia.[26, 27, 28, 29] From a  
118 systems biology perspective, the convention of single or limited series measurement of glucose  
119 testing may be inadequate to detect downstream dysfunction, setting the stage for more dense  
120 sampling and real-world evidence as obtained with continuous glucose monitoring (CGM) and  
121 potentially better diagnostic accuracy.[30]

122  
123 Our goal is to interrogate the glycemic system as it shifts from health to predisease in  
124 nondiabetic patients utilizing CGM metrics. New insights may offer therapeutic promise for

1  
2  
3 125 reversing dysglycaemia more successfully with dietary, nutritional, and lifestyle change before  
4 126 progression occurs to prediabetes and diabetes.  
5 127

### 6 128 **Objectives**

7 129 This systematic review aims to answer the questions:  
8 130

- 9 131 1. How do continuous glucose monitoring metrics differ between euglycaemia and  
10 132 prediabetes?
- 11 133 2. What is the relation (correlation) between CGM dynamic metrics and established  
12 134 diagnostic criteria?
- 13 135 3. What is the diagnostic power of CGM dynamic metrics?  
14 136

## 15 137

### 16 138 **METHODS AND ANALYSIS**

17 139  
18 140 The protocol for the present systematic review and meta-analysis follows the Preferred Reporting  
19 141 Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines,[31] and the  
20 142 Cochrane Handbook of Systematic Reviews of Interventions.[32]  
21 143

22 144 The protocol has been submitted for registration with the National Institute for Health Research  
23 145 (NIHR) International Prospective Register of Systematic Reviews (CRD pending).  
24 146

### 25 147 **Eligibility criteria**

26 148 A summary of the participants, interventions, comparators, and outcomes considered, as well as  
27 149 the type of studies included according to PICOS strategy,[33] is provided below.  
28 150

#### 29 151 Population

30 152 The target population is adults (> 18 years old) who are diagnosed with prediabetes (fasting  
31 153 glucose 100-125 mg/dL after a minimum 8-hour fast, and/or hemoglobin A1C 5.7-6.4%, and/or  
32 154 2-hour oral glucose tolerance test with glucose 140-199 mg/dL) as defined by the American  
33 155 Diabetes Association (ADA), <https://www.diabetes.org/a1c/diagnosis>, accessed January 24,  
34 156 2022. We will use the criteria of fasting glucose 100-125 mg/dL or hemoglobin A1C of 5.7-6.4%  
35 157 since the 2-hour oral glucose tolerance test is less commonly used in clinical practice, but we  
36 158 will extract the data if available. In order to create the most homogenous pool of studies to  
37 159 address our research questions in nondiabetic adults, studies that include only participants under  
38 160 the age of 18, above the age of 65, or diagnosed with Type 1 and/or Type 2 diabetes will be  
39 161 excluded. Studies will also be excluded if focused on subjects with acute illness or systemic  
40 162 chronic disease (e.g., liver, kidney, stroke, coronary artery disease).  
41 163

#### 42 164 Intervention

43 165 We will evaluate primary studies that report outcomes of the use of CGM in patients with  
44 166 prediabetes and/or healthy subjects.  
45 167

#### 46 168 Comparison

47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

Potentially relevant CGM biomarkers are identified by comparing prediabetes values to values for healthy controls (fasting glucose < 100 mg/dL, and/or hemoglobin A1C < 5.7%, and/or 2-hour oral glucose tolerance test with glucose <140 mg/dL).

CGM biomarkers are then compared to standard diagnostics for prediabetes.

### Outcomes

In order to explore and define novel CGM biomarkers to predict transition from normal to prediabetic phenotype, the following outcomes are considered:

- CGM metrics include mean, SD, CV, CONGA, MAGE, MAG, M-value, HBGI, LBGI, J-index, L-index, GRADE, % Time in range, % Time below range, % Time above range). (Note that the definition of time in range may vary by author, which will be addressed in the systematic review.)
- Pearson correlation coefficient and results of error grid analysis between the CGM system metrics and established glucose monitoring methods (fasting glucose, hemoglobin A1C, 2-hour oral glucose tolerance test).
- CGM metrics diagnostic power (e.g., sensitivity, specificity, area under the curve, diagnostic odds ratio).

### Study design

This review includes observational (e.g., case report, case series, cross-sectional, case-control, cohort) and interventional (e.g., quasi-experimental studies, randomized controlled trials, community trials, field trials) primary, peer-review studies in which CGM is the only intervention under investigation. We will exclude reviews, editorials, commentaries, letters, opinions, meta-analysis, case reports, conference abstracts, comments, preclinical (in-vitro; animal model) studies, and clinical trials involving additional interventions. Studies will be restricted to the English language and published in the last 10 years, since for technologies that evolve and improve rapidly, like CGM, the more recent studies (using the technology closer to the current one) are majorly relevant.

### **Search methods for identifying studies**

#### Sources of studies

We will conduct systematic searches of the PubMed, Scopus, Cochrane Library, and ClinicalTrials.gov databases. Searches will be limited to studies published in English within 10 years of the time of conducting the search. We will additionally search for unpublished studies in grey literature, by reviewing abstracts from a targeted group of conference proceedings for potential inclusion of additional studies. When available, the proceedings of these conferences from 2012 to 2022 will be searched: Precision Nutrition and Metabolism Conference; Harvard Precision Medicine Annual Conference; International Precision Medicine Conference; and Precision Medicine World Conference.

#### Search strategy

A medical librarian on the review team developed a comprehensive search strategy encompassing the aims of the systematic review. The strategy combines four sets of terms with Boolean operators: 1) terms related to prediabetes; 2) terms related to continuous glucose monitoring; 3) terms related to diagnostic criteria for prediabetes; and 4) terms related to

1  
2  
3 215 diagnostic accuracy and the prediction of transition. Each set of terms includes both keywords  
4 216 searched in the title/abstract field and database-specific subject headings. Terms within each set  
5 217 are combined with the operator OR. The four sets of terms are then combined with the operator  
6 218 AND, yielding studies that include at least one term from each set. The initial search strategy  
7 219 was developed in PubMed (see online supplementary file 1). The strategy will be translated into  
8 220 the other included databases, using appropriate subject headings for each database.  
9 221

### 222 Study selection

13 223 All records identified in the database search will be uploaded to Covidence systematic review  
14 224 software (<https://www.covidence.org>) for automatic deduplication and blinded screening,  
15 225 conflict resolving, study selection and data extraction. Two authors will independently perform  
16 226 the initial primary article screening based on the information contained in their titles and  
17 227 abstracts, and categorize them into three groups: relevant, irrelevant and unsure. In case of  
18 228 disagreement, the article will be re-evaluated and, if the disagreement persist, a third reviewer  
19 229 will make a final decision. Full-paper screening will then be conducted by the same independent  
20 230 investigators and a list of articles to be included in the review is compiled. Reference lists of  
21 231 articles that meet eligibility criteria in the screening process will subsequently be screened for  
22 232 potential inclusion of additional studies.  
23 233

### 234 **Data extraction**

25 235 Two independent authors will extract data from the final studies identified as eligible to be  
26 236 included in the review using a predesigned pilot-tested data collection form using the Covidence  
27 237 extraction module. Eventual discrepancies will be addressed with a third reviewer and discussed  
28 238 until consensus is reached.

29 239 The data to be extracted will include:

- 30 240 1. Publication details: authors, title, journal, year of publication, country in which the study  
31 241 was conducted and funding source(s).
- 32 242 2. Study design: type of study, inclusion and exclusion criteria, method of recruitment of  
33 243 participants, limitations and mitigation strategies.
- 34 244 3. Participant details: sample size, demographic information (e.g. age, gender,  
35 245 comorbidities).
- 36 246 4. Intervention characteristics: CGM device brand and model, CGM duration, aim of  
37 247 intervention.
- 38 248 5. Study outcomes: CGM metrics, correlation between CGM metrics and established  
39 249 diagnostic criteria.

40 250 In cases of missing, incomplete, or unclear data in the included studies, we will attempt to  
41 251 contact study authors for further information.  
42 252

### 43 253 **Risk of Bias**

44 254 The Cochrane Collaboration risk of bias tools will be used to assess the risk of bias in the studies that  
45 255 meet inclusion criteria.[34, 35, 36] This will be assessed independently by two reviewers, with  
46 256 conflicts resolved by a third reviewer.  
47 257

### 48 258 **Data synthesis and analysis**

49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



259 Data will be entered into a custom database and a narrative synthesis will summarize the findings  
260 of the review by organizing data into a systematic narrative review, tables, and figures of data  
261 extraction. For continuous outcomes analysis will be performed using standardized mean  
262 differences (SMD) or mean differences (MD) with its respective 95% CIs. Binary outcomes will  
263 be analyzed and reported using risk ratio (RR) or odds ratio (OR) with its respective 95% CIs.  
264 Studies with similar characteristics and outcomes will be grouped and, where suitable data and  
265 homogeneity exist, a meta-analysis will be performed using random effects models. A combined  
266 Pearson correlation coefficient between CGM metrics and established diagnostic criteria (i.e.,  
267 fasting plasma glucose, hemoglobin A1C, 2-hour oral glucose tolerance test) and according 95%  
268 CI will also be calculated. If sufficient data are available, subgroup analysis will be carried out to  
269 explore CGM metrics estimates for prediabetes stratified by age, sex, race and ethnicity, type of  
270 CGM device, and body mass index.

### 271 272 **Patient and Public Involvement**

273 As this research will be based on previously published data, there will be no patient and  
274 members of the public involvement in the design, interpretation or dissemination of the findings.  
275

### 276 **DISCUSSION**

277  
278 This systematic review will provide important information about the benefits of adding CGM to  
279 standard diagnostic measures in the diagnosis of euglycaemia versus prediabetes. Currently,  
280 there are many challenges that exist with the diagnosis of prediabetes.[37] The technology,  
281 emerging algorithms, and more comprehensive data set have shown promise distinguishing  
282 euglycemic from prediabetic subjects at an earlier stage, and likely before standard measures  
283 such as HbA1C show abnormalities. Previously, Hall et al. discovered that in individuals  
284 considered to be euglycemic by single or episodic measurement, CGM identifies an additional  
285 15% of patients with prediabetes and 2% with diabetes, suggesting that dysglycaemia is more  
286 prevalent than previously understood and that CGM metrics may be a more sensitive indicator of  
287 dysglycaemia, though the cost is certainly higher[38] The findings will inform further work that  
288 will aim to more fully characterize the stages in the transition from health to prediabetes,  
289 potentially providing a mechanism for patients to be more involved and empowered to reverse  
290 dysglycaemia in response to food and lifestyle factors. There are several limitations to the  
291 current review protocol. The review will be restricted to published studies in the last 10 years,  
292 which introduces publication bias. Secondly, only studies written in English language will be  
293 included, introducing language bias. Thirdly, we acknowledge that CGM values in nondiabetic  
294 subjects are not linked with hard outcomes like retinopathy or nephropathy, so that the clinical  
295 relevance of our findings will remain associative only. Finally, we note that CGMs have not been  
296 validated by any health agency for any form of diabetes or nondiabetes and that the identified  
297 CGM metrics are exploratory.

### 298 299 **Ethics and dissemination**

300 Owing to the study design of systematic reviews and meta-analyses, ethics approval is not  
301 necessary. The systematic review will be published in a peer-reviewed journal and presented at  
302 appropriate conferences. This protocol will be adapted for the analysis of other classes of  
303 biomarkers for prediabetes.  
304

### 305 **Authors' contributions**

306 SG was involved with conceptualization, methodology, preliminary systematic review, formal  
307 analysis, writing the protocol manuscript, study supervision, and project administration; LP was  
308 involved in project conception and development, methodology, preliminary systematic review,  
309 formal analysis, study supervision, acquisition of data, data analysis and writing the protocol;  
310 AN was involved in conceptualization, study supervision and writing the manuscript; GL was  
311 involved in systematic review search strategy development, registration of the protocol in  
312 Prospero, and writing of the protocol manuscript; DM was involved in project conception and  
313 development, and writing the protocol manuscript. All authors read and approved the final  
314 manuscript.

### 316 **Funding statement**

317 This research received no specific grant from any funding agency in the public, commercial or  
318 not for profit sector.

### 320 **Competing interests**

321 None

### 323 **REFERENCES**

1 Centers for Disease Control and Prevention. What is diabetes?

<https://www.cdc.gov/diabetes/basics/diabetes.html>, accessed 3/19/21

2 American Diabetes Association: Standards of medical care in diabetes—2007. *Diabetes Care* 2007;30(Suppl1):S4–S41.

3 Tseng E, Greer RC, O'Rourke P, *et al.* National Survey of Primary Care Physicians' Knowledge, Practices, and Perceptions of Prediabetes. *J Gen Intern Med.* 2019;34(11):2475-2481. doi:10.1007/s11606-019-05245-7

4 Thomas TW, Golin C, Samuel-Hodge CD, *et al.* Race and gender differences in abnormal blood glucose screening and clinician response to prediabetes: A mixed-methods assessment. *Prev Med.* 2021;148:106587.

5 Siegelaar SE, Holleman F, Hoekstra JB, *et al.* Glucose variability: does it matter? *Endocr Rev* 2010;31:171–182.

6 Weykamp, C. HbA1c: a review of analytical and clinical aspects. *Annals of laboratory medicine* vol 2013;33(6): 393-400.

7 Shepard JG, Airee A, Dake AW, *et al.* Limitations of A1c Interpretation. *Southern medical journal* vol. 108,12 (2015): 724-9.

8 Nomura K, Saitoh T, Kim GU, *et al.* Glycemic profiles of healthy individuals with low fasting plasma glucose and HbA1c. *ISRN Endocrinology.* 2011;2011(435047):6.

- 1  
2  
3  
4  
5  
6  
7  
8  
9
- 9 Salkind S, Huizenga R, Fonda S, et al. Glycemic variability in nondiabetic morbidly obese persons: results of an observational study and review of the literature. *J Diabet Sci Technol* 2014;8(5):1042–7.
- 10 Genuth S, Alberti KG, Bennett P, et al. Expert committee on the diagnosis and classification of diabetes mellitus. follow-up report on the diagnosis of diabetes mellitus. *Diabetes Care*. 2003;26(11):3160-7.
- 11 Brambilla P, La Valle E, Falbo R, et al. “Normal fasting plasma glucose and risk of type 2 diabetes.” *Diabetes care* vol. 34,6 (2011): 1372-4.
- 12 Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. *JAMA*. 2006;295(14):1681-7.
- 13 Esposito K, Nappo F, Marfella R, et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. *Circulation*. 2002;106(16):2067-72.
- 14 Altıncık A, Tuğlu B, Demir K, et al. Relationship between oxidative stress and blood glucose fluctuations evaluated with daily glucose monitoring in children with type 1 diabetes mellitus. *J Pediatr Endocrinol Metab*. 2016;29(4):435-9.
- 15 Hanefeld M, Sulk S, Helbig M, et al. Differences in glycemic variability between normoglycemic and prediabetic subjects. *J Diabet Sci Technol*. 2014;8(2):286–90.
- 16 Buscemi S, Re A, Batsis JA, et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes. *Diabetes Med* 2010;27:872–8.
- 17 Buscemi S, Re A, Batsis JA, et al. Glycaemic variability using continuous glucose monitoring and endothelial function in the metabolic syndrome and in Type 2 diabetes. *Diabetes Med* 2010;27:872–8.
- 18 Luchsinger JA, Tang MX, Shea S, et al. “Hyperinsulinemia and risk of Alzheimer disease.” *Neurology* 2004;63(7): 1187-92.
- 19 Emerging Risk Factors Collaboration, Sarwar N, Gao P, et al. “Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies.” *Lancet* 2010;375(9733):2215-22.
- 52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 
- <sup>20</sup> Lawlor DA, Fraser A, Ebrahim S, et al. Independent associations of fasting insulin, glucose, and glycated haemoglobin with stroke and coronary heart disease in older women. *PLoS Med.* 2007 Aug;4(8):e263
- <sup>21</sup> Ahn SV, Kim HC, Nam CM, et al. Sex difference in the effect of the fasting serum glucose level on the risk of coronary heart disease. *J Cardiol.* 2018 Feb;71(2):149-154.
- <sup>22</sup> Ceriello A, Hanefeld M, Leiter L, et al. "Postprandial glucose regulation and diabetic complications." *Archives of internal medicine* 2004;164(19):2090-5.
- <sup>23</sup> Shaw JE, Hodge AM, de Courten M, et al. "Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality." *Diabetologia* 1999;42(9):1050-4.
- <sup>24</sup> Moore, KB. "Glucose fluctuations and oxidative stress." *JAMA* 2006;296(14):1730.
- <sup>25</sup> Sampson MJ, Gopaul N, Davies IR, et al. Plasma F2 isoprostanes: direct evidence of increased free radical damage during acute hyperglycemia in type 2 diabetes. *Diabetes Care.* 2002;25(3):537-41.
- <sup>26</sup> Zou CC, Liang L, Hong F, et al. "Glucose metabolism disorder in obese children assessed by continuous glucose monitoring system." *World journal of pediatrics: WJP* 2008;4(1): 26-30.
- <sup>27</sup> Lee D, Dreyfuss JM, Sheehan A, et al. Glycemic patterns are distinct in post-bariatric hypoglycemia after gastric bypass (PBH-RYGB). *J Clin Endocrinol Metab.* 2021;106(8):2291-2303.
- <sup>28</sup> Bialasiewicz P, Pawlowski M, Nowak D, et al. Decreasing concentration of interstitial glucose in REM sleep in subjects with normal glucose tolerance. *Diabet Med.* 2009;26(4):339-344.
- <sup>29</sup> Wang C, Lv L, Yang Y, et al. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. *Clin Endocrinol.* 2012;76:810-5.
- <sup>30</sup> Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose dysregulation. *PLoS Biology.* 2018;16(7):e2005143.
- <sup>31</sup> Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. *Syst Rev* 2015;4:1
- <sup>32</sup> Higgins JPT, Green S. *Cochrane handbook for systematic reviews of interventions* (version 6.1). The Cochrane Collaboration; 2020. <http://www.handbook.cochrane.org>. Accessed January 28, 2022.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

---

<sup>33</sup> The Cochrane Collaboration. Part 2 Chapter 3: Defining the criteria for including studies and how they will be grouped for the synthesis In: Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions (version 6.1). The Cochrane Collaboration; 2020. <http://www.handbook.cochrane.org>. Accessed January 28, 2022.

<sup>34</sup> Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. *BMJ*. 2011;343:d5928. Published 2011 Oct 18. doi:10.1136/bmj.d5928

<sup>35</sup> Sterne JA, Hernán MA, Reeves BC, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. *BMJ* 2016;355:i4919.

<sup>36</sup> Sterne JAC, Savović J, Page MJ, Elbers RG, Blencowe NS, Boutron I, Cates CJ, Cheng H-Y, Corbett MS, Eldridge SM, Hernán MA, Hopewell S, Hróbjartsson A, Junqueira DR, Jüni P, Kirkham JJ, Lasserson T, Li T, McAleenan A, Reeves BC, Shepperd S, Shrier I, Stewart LA, Tilling K, White IR, Whiting PF, Higgins JPT. RoB 2: a revised tool for assessing risk of bias in randomised trials. *BMJ* 2019; **366**: i4898.

<sup>37</sup> Bansal N. Prediabetes diagnosis and treatment: A review. *World J Diabetes*. 2015;6(2):296-303. doi:10.4239/wjd.v6.i2.296.

<sup>38</sup> Hall H, Perelman D, Breschi A, et al. Glucotypes reveal new patterns of glucose dysregulation. *PLoS Biology*. 2018;16(7):e2005143.

1  
2  
3 (((("diabetes prevention" [title/abstract] OR "diabetes risk\*" [title/abstract] OR "diabetes susceptibility"  
4 [title/abstract] OR "prediabet\*" [title/abstract] OR "pre-diabet\*" [title/abstract] OR "prediabetic state"  
5 [mesh]) AND ("blood glucose self-monitoring" [mesh] OR "blood sugar self monitor\*" [title/abstract] OR  
6 "blood sugar self-monitor\*" [title/abstract] OR "CGM" [title/abstract] OR "CGMS" [title/abstract] OR  
7 "glucose monitor\*" [title/abstract] OR "glucose self monitor\*" [title/abstract] OR "glucose self-monitor\*" [title/abstract] OR "monitoring, ambulatory" [mesh] OR "monitoring, physiologic/instrumentation"  
8 [mesh] OR "monitoring, physiologic/methods" [mesh] OR "personalized medicine" [title/abstract] OR  
9 "precision medicine" [mesh] OR "precision medicine" [title/abstract] OR "RT-CGM" [title/abstract]))  
10 AND ("biomarker\*" [title/abstract] OR "biomarkers/analysis" [mesh] OR "biomarkers/blood" [mesh] OR  
11 "blood chemical analys\*" [title/abstract] OR "blood chemical analysis" [mesh] OR "blood glucose self-  
12 monitoring/statistics and numerical data" [mesh] OR "blood glucose/analysis" [mesh] OR "criteria"  
13 [title/abstract] OR "deviation\*" [title/abstract] OR "dysglycemia" [title/abstract] OR "euglycemi\*"  
14 [title/abstract] OR "euglycaemi\*"  
15 [title/abstract] OR "fluctuation\*" [title/abstract] OR "glucose tolerance  
16 test" [mesh] OR "glucose" [title/abstract] OR "glucotype\*" [title/abstract] OR "glycaemic" [title/abstract]  
17 OR "glycated hemoglobin A/analysis" [mesh] OR "glycated hemoglobin A/statistics and numerical data"  
18 [mesh] OR "glycemic" [title/abstract] OR "HbA1c" [title/abstract] OR "hemoglobin A1c" [title/abstract]  
19 OR "hyperglycemia" [mesh] OR "hyperglycemia" [title/abstract] OR "metric\*" [title/abstract] OR  
20 "normal\*" [title/abstract] OR "normoglycemic\*" [title/abstract] OR "phenotyp\*" [title/abstract] OR  
21 "prediabetic state/analysis" [mesh] OR "prediabetic state/blood" [mesh] OR "prediabetic state/blood"  
22 [mesh] OR "prediabetic state/statistics and numerical data" [mesh] OR "reference values" [mesh] OR  
23 "reference\*" [title/abstract] OR "screening\*" [title/abstract] OR "standard\*" [title/abstract] OR "test\*" [title/abstract] OR "variability" [title/abstract] OR "variation\*" [title/abstract])) AND ("detect\*" [title/abstract] OR "diagnos\*" [title/abstract] OR "disease progression" [mesh] OR "early diagnosis" [mesh] OR "early medical intervention" [mesh] OR "identif\*" [title/abstract] OR "prediabet\*" [title/abstract] OR "pre-diabet\*" [title/abstract] OR "prediabetic state/classification" [mesh] OR "prediabetic state/diagnosis" [mesh] OR "prediabetic state/prevention and control" [mesh] OR "prediabetic\*" [title/abstract] OR "pre-diabetic\*" [title/abstract] OR "predict\*" [title/abstract] OR "predictive value of tests" [mesh] OR "prevent\*" [title/abstract] OR "progression\*" [mesh] OR "risk assessment" [mesh] OR "risk factors" [mesh] OR "risk\*" [title/abstract] OR "transition\*" [title/abstract])) AND ((english[Filter])) AND ((y\_10[Filter]))  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## PRISMA-P (Preferred Reporting Items for Systematic review and Meta-Analysis Protocols) 2015 checklist: recommended items to address in a systematic review protocol\*

Section and topic	Item No	Checklist item
<b>ADMINISTRATIVE INFORMATION</b>		
Title:		
Identification	1a	Identify the report as a protocol of a systematic review <b>Page 1 – Line 2</b>
Update	1b	If the protocol is for an update of a previous systematic review, identify as such <b>N/A</b>
Registration	2	If registered, provide the name of the registry (such as PROSPERO) and registration number <b>Page 2 – Line 57</b>
Authors:		
Contact	3a	Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical mailing address of corresponding author <b>Page 1 – Lines 4-25</b>
Contributions	3b	Describe contributions of protocol authors and identify the guarantor of the review <b>Page 8 – Lines 305-314</b>
Amendments	4	If the protocol represents an amendment of a previously completed or published protocol, identify as such and list changes; otherwise, state plan for documenting important protocol amendments <b>N/A</b>
Support:		
Sources	5a	Indicate sources of financial or other support for the review <b>Page 8 – Lines 316-317</b>
Sponsor	5b	Provide name for the review funder and/or sponsor <b>Page 8 – Line 317</b>
Role of sponsor or funder	5c	Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol <b>Page 8 – Line 317</b>
<b>INTRODUCTION</b>		
Rationale	6	Describe the rationale for the review in the context of what is already known <b>Page 3 – Lines 88-121</b>
Objectives	7	Provide an explicit statement of the question(s) the review will address with reference to participants, interventions, comparators, and outcomes (PICO) <b>Pages 3 &amp; 4 – Lines 123-135</b>
<b>METHODS</b>		
Eligibility criteria	8	Specify the study characteristics (such as PICO, study design, setting, time frame) and report characteristics (such as years considered, language, publication status) to be used as criteria for eligibility for the review <b>Pages 4 &amp; 5 – Lines 147-196</b>
Information sources	9	Describe all intended information sources (such as electronic databases, contact with study authors, trial registers or other grey literature sources) with planned dates of coverage <b>Page 5 – Lines 200-208</b>
Search strategy	10	Present draft of search strategy to be used for at least one electronic database, including planned limits, such that it could be repeated <b>Pages 5 &amp; 6 – Lines 210-220</b>
Study records:		
Data management	11a	Describe the mechanism(s) that will be used to manage records and data throughout the review <b>Page 6 – Lines 223-225</b>

Selection process	11b	State the process that will be used for selecting studies (such as two independent reviewers) through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) <a href="#">Page 6 – Lines 225-232</a>
Data collection process	11c	Describe planned method of extracting data from reports (such as piloting forms done independently, in duplicate), any processes for obtaining and confirming data from investigators <a href="#">Page 6 – Lines 234-238</a>
Data items	12	List and define all variables for which data will be sought (such as PICO items, funding sources), any pre-planned data assumptions and simplifications <a href="#">Page 6 – Lines 239-251</a>
Outcomes and prioritization	13	List and define all outcomes for which data will be sought, including prioritization of main and additional outcomes, with rationale <a href="#">Page 5 – Lines 174-185</a>
Risk of bias in individual studies	14	Describe anticipated methods for assessing risk of bias of individual studies, including whether this will be done at the outcome or study level, or both; state how this information will be used in data synthesis <a href="#">Page 6 – Lines 253-256</a>
Data synthesis	15a	Describe criteria under which study data will be quantitatively synthesised <a href="#">Page 6 – Lines 259-261</a>
	15b	If data are appropriate for quantitative synthesis, describe planned summary measures, methods of handling data and methods of combining data from studies, including any planned exploration of consistency (such as $I^2$ , Kendall's $\tau$ ) <a href="#">Page 7 – Lines 261-270</a>
	15c	Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-regression) <a href="#">N/A</a>
	15d	If quantitative synthesis is not appropriate, describe the type of summary planned <a href="#">N/A</a>
Meta-bias(es)	16	Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective reporting within studies) <a href="#">Page 6 – Lines 253-256</a>
Confidence in cumulative evidence	17	Describe how the strength of the body of evidence will be assessed (such as GRADE) <a href="#">Page 6 – Lines 253-256</a>

**\* It is strongly recommended that this checklist be read in conjunction with the PRISMA-P Explanation and Elaboration (cite when available) for important clarification on the items. Amendments to a review protocol should be tracked and dated. The copyright for PRISMA-P (including checklist) is held by the PRISMA-P Group and is distributed under a Creative Commons Attribution Licence 4.0.**

*From: Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart L, PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. *BMJ*. 2015 Jan 2;349(jan02 1):g7647.*